{
    "2020-07-07": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Novartis Gets EC Approval for Enerzair Breezhaler for Asthma",
                "features": {
                    "keywords": [
                        "Novartis",
                        "EC Approval",
                        "Enerzair Breezhaler",
                        "Asthma"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "The Zacks Analyst Blog Highlights: Novartis, Equinix, Newmont, Enterprise Products Partners and Franco-Nevada",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Novartis",
                        "Equinix",
                        "Newmont",
                        "Enterprise Products Partners",
                        "Franco-Nevada"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "real estate",
                        "mining",
                        "energy"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "The Daily Biotech Pulse: Novavax Lands $1.6B For COVID-19 Vaccine, Amgen Prevails In Avastin Biosimilar Lawsuit, Cellectis Study Placed On Clinical Hold",
                "features": {
                    "keywords": [
                        "Novavax",
                        "COVID-19 Vaccine",
                        "Amgen",
                        "Avastin Biosimilar",
                        "Cellectis",
                        "Clinical Hold"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Yates Class Action Law Encourages Long Term Stockholders of Novartis AG (NYSE: NVS) to Contact The Firm",
                "features": {
                    "keywords": [
                        "Class Action",
                        "Novartis AG",
                        "Stockholders"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "legal",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}